BR0111571A - Inibidores de reductase de hmg-coa e seu uso como medicamentos para o tratamento de doenças relacionadas ao colesterol - Google Patents
Inibidores de reductase de hmg-coa e seu uso como medicamentos para o tratamento de doenças relacionadas ao colesterolInfo
- Publication number
- BR0111571A BR0111571A BR0111571-5A BR0111571A BR0111571A BR 0111571 A BR0111571 A BR 0111571A BR 0111571 A BR0111571 A BR 0111571A BR 0111571 A BR0111571 A BR 0111571A
- Authority
- BR
- Brazil
- Prior art keywords
- cholesterol
- hmg
- coa reductase
- treatment
- related diseases
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 235000012000 cholesterol Nutrition 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
Abstract
"INIBIDORES DE REDUCTASE DE HMG-COA E SEU USO COMO MEDICAMENTOS PARA O TRATAMENTO DE DOENçAS RELACIONADAS AO COLESTEROL". Compostos das seguintes estruturas são inibidores de HMG CoA reductase e assim são ativos na inibição de biossíntese de colesterol, modulação de lipídios do soro do sangue , por exemplo, redução do colesterol LDL e/ou aumento do colesterol HDL, e tratamento de hiperlipidemia, dislipidemia, terapia de substituição de hormónio, hipercolesterolemia, hipertrigliceridemia e arteriosclerose assim como mal de Alzheimer e osteroporose e sais farmaceuticamente aceitáveis dos mesmos, z é n é O ou 1; x é 0, 1, 2, 3 ou 4; y é 0, 1, 2, 3, ou 4, desde que pelo menos um de x e y seja diferente de 0; e opcionalmente um ou mais carbonos de (CH~ 2~)~ x~ e/ou (CH~ 2~)~ y~ podem formar parte de um anel com 3 a 7 membros espirocíclico; R~ 1~ e R~ 2~ são iguais ou diferentes e são independentemente selecionados de alquila, arilalquila, cicloalquila, alquenila, cicloalquenila, arila, heteroarila ou cicloheteroalquila; R~ 3~ é H ou alquila inferior; R~ 4~ e R~ 7~ são conforme aqui definido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21159400P | 2000-06-15 | 2000-06-15 | |
| PCT/US2001/018868 WO2001096311A2 (en) | 2000-06-15 | 2001-06-12 | Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0111571A true BR0111571A (pt) | 2003-07-01 |
Family
ID=22787566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0111571-5A BR0111571A (pt) | 2000-06-15 | 2001-06-12 | Inibidores de reductase de hmg-coa e seu uso como medicamentos para o tratamento de doenças relacionadas ao colesterol |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20020028826A1 (pt) |
| EP (1) | EP1294696A2 (pt) |
| JP (1) | JP2004503541A (pt) |
| KR (1) | KR20030010720A (pt) |
| CN (1) | CN1436174A (pt) |
| AR (1) | AR028732A1 (pt) |
| AU (1) | AU2001266860A1 (pt) |
| BR (1) | BR0111571A (pt) |
| CA (1) | CA2412979A1 (pt) |
| CZ (1) | CZ20023931A3 (pt) |
| EC (1) | ECSP024386A (pt) |
| HU (1) | HUP0302955A3 (pt) |
| IL (1) | IL152718A0 (pt) |
| MX (1) | MXPA02012415A (pt) |
| NO (1) | NO20026011L (pt) |
| PE (1) | PE20011364A1 (pt) |
| PL (1) | PL362477A1 (pt) |
| UY (1) | UY26776A1 (pt) |
| WO (1) | WO2001096311A2 (pt) |
| ZA (1) | ZA200210102B (pt) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110196039A9 (en) * | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
| AP2003002743A0 (en) * | 2000-08-15 | 2003-03-31 | Pfizer Prod Inc | Therapeutic combination of a cept inhibitor and atorvastatin |
| MXPA03011195A (es) * | 2001-06-06 | 2004-03-18 | Bristol Myers Squibb Co | Proceso para preparacion de sulfonas de diol quirales e inhibidores de coa-reductasa del dihidroxiacido hmg. |
| JP2004536845A (ja) | 2001-07-11 | 2004-12-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療方法 |
| EP1435946B8 (en) | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| WO2003090723A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| AU2003248077A1 (en) * | 2002-07-18 | 2004-02-09 | Sankyo Company, Limited | Medicinal composition for treating arteriosclerosis |
| US20050192245A1 (en) * | 2002-07-18 | 2005-09-01 | Sankyo Company, Limited | Medicinal composition for treating arteriosclerosis |
| US7585866B2 (en) * | 2002-07-31 | 2009-09-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| AU2003273675A1 (en) * | 2002-10-09 | 2004-05-04 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| KR20110117731A (ko) | 2003-05-30 | 2011-10-27 | 랜박시 래보러터리스 리미티드 | 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도 |
| US20070161700A1 (en) | 2004-12-28 | 2007-07-12 | Kowa Company, Ltd. | Inhibitor for the formation of y-secretase complex |
| EP1729761A4 (en) * | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS |
| MXPA06011969A (es) * | 2004-04-14 | 2006-12-15 | Warner Lambert Co | Combinacion terapeutica para tratamiento de la enfermedad de alzheimer. |
| ES2282062T1 (es) | 2004-06-04 | 2007-10-16 | Teva Pharmaceutical Industries Ltd. | Composicion farmaceutica que contiene irbesartan. |
| US20070112050A1 (en) * | 2005-04-12 | 2007-05-17 | Psivida Inc. | HMGCoA reductase inhibitor combinations and uses thereof |
| WO2007016306A2 (en) * | 2005-08-01 | 2007-02-08 | Psivida Inc. | HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF |
| CA2627599A1 (en) | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
| EP2526937A1 (en) * | 2006-02-07 | 2012-11-28 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of recurrence of stroke |
| CN101438155B (zh) * | 2006-02-27 | 2013-04-24 | 靶向分子诊断有限责任公司 | 一种预测使用酪氨酸激酶抑制剂的处理的心脏毒性的方法 |
| CA2645281A1 (en) | 2006-03-29 | 2007-10-04 | Kowa Co., Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
| WO2008059519A2 (en) * | 2006-09-25 | 2008-05-22 | Glenmark Pharmaceuticals Limited | A process for the preparation of intermediates of rosuvastatin |
| JP5571387B2 (ja) | 2007-01-11 | 2014-08-13 | クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド | 癌の治療のための化合物および方法 |
| US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| KR100900044B1 (ko) * | 2007-07-05 | 2009-06-01 | 한국식품연구원 | 3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제 |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| CA2710039C (en) * | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| KR101104335B1 (ko) * | 2009-03-06 | 2012-01-16 | 가톨릭대학교 산학협력단 | 알카노일화된 히알루론산으로 형성된 나노입자 및 그 제조방법 |
| CA2999435A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| US9056134B2 (en) * | 2010-07-21 | 2015-06-16 | Nucitec S.A. De C.V. | Single daily dosage form for prevention and treatment of metabolic syndrome |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| US8865900B2 (en) | 2011-01-18 | 2014-10-21 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Methyltetrazole sulfides and sulfones |
| WO2012098048A1 (en) | 2011-01-18 | 2012-07-26 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Process for the preparation of diol sulfones |
| MX357470B (es) | 2011-01-18 | 2018-07-11 | Dsm Sinochem Pharm Nl Bv | Procedimiento para la preparación de estatinas en presencia de base. |
| US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| CA2853804C (en) | 2011-10-28 | 2021-06-01 | Vitalis Llc | Anti-flush compositions |
| MX359424B (es) | 2011-12-09 | 2018-09-12 | Dsm Sinochem Pharm Nl Bv | Proceso para la preparación de un precursor de estatina. |
| SI2788341T1 (sl) | 2011-12-09 | 2017-06-30 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Postopek za pripravo tioprekurzorja za statine |
| JP6041985B2 (ja) * | 2012-06-08 | 2016-12-14 | ミレ ファイン ケミカル カンパニー リミテッド | 結晶型ｔ−ブチル２−［（４Ｒ，６Ｓ）−６−ホルミル−２，２−ジメチル−１，３−ジオキサン−４−イル］アセテート及びその製造方法 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN112159403B (zh) | 2020-09-30 | 2022-04-15 | 复旦大学 | 一种用于合成他汀类药物的关键中间体的制备方法 |
| CN114394961A (zh) * | 2021-12-24 | 2022-04-26 | 江苏阿尔法药业股份有限公司 | 用臭氧做氧化剂制备瑞舒伐他汀钙中间体的方法 |
| CN114213350B (zh) * | 2021-12-29 | 2024-03-19 | 江苏福瑞康泰药业有限公司 | 一种他汀类药物中间体的制备方法 |
| CN114437052B (zh) * | 2021-12-31 | 2024-03-29 | 江苏阿尔法集团福瑞药业(宿迁)有限公司 | 一种利用连续流微通道反应器合成他汀类药物中间体的方法 |
| CN114601039A (zh) * | 2022-03-16 | 2022-06-10 | 江苏省农业科学院 | 一种提高热应激下绵羊发情率和受胎率的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
-
2001
- 2001-06-06 US US09/875,218 patent/US20020028826A1/en not_active Abandoned
- 2001-06-12 HU HU0302955A patent/HUP0302955A3/hu unknown
- 2001-06-12 CZ CZ20023931A patent/CZ20023931A3/cs unknown
- 2001-06-12 KR KR1020027017087A patent/KR20030010720A/ko not_active Withdrawn
- 2001-06-12 MX MXPA02012415A patent/MXPA02012415A/es unknown
- 2001-06-12 EP EP01944449A patent/EP1294696A2/en not_active Withdrawn
- 2001-06-12 CA CA002412979A patent/CA2412979A1/en not_active Abandoned
- 2001-06-12 WO PCT/US2001/018868 patent/WO2001096311A2/en not_active Ceased
- 2001-06-12 IL IL15271801A patent/IL152718A0/xx unknown
- 2001-06-12 AU AU2001266860A patent/AU2001266860A1/en not_active Abandoned
- 2001-06-12 CN CN01811219A patent/CN1436174A/zh active Pending
- 2001-06-12 JP JP2002510454A patent/JP2004503541A/ja active Pending
- 2001-06-12 BR BR0111571-5A patent/BR0111571A/pt not_active IP Right Cessation
- 2001-06-12 PL PL01362477A patent/PL362477A1/xx not_active Application Discontinuation
- 2001-06-15 PE PE2001000579A patent/PE20011364A1/es not_active Application Discontinuation
- 2001-06-15 UY UY26776A patent/UY26776A1/es not_active Application Discontinuation
- 2001-06-15 AR ARP010102885A patent/AR028732A1/es not_active Application Discontinuation
-
2002
- 2002-12-12 EC EC2002004386A patent/ECSP024386A/es unknown
- 2002-12-12 ZA ZA200210102A patent/ZA200210102B/en unknown
- 2002-12-13 NO NO20026011A patent/NO20026011L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1436174A (zh) | 2003-08-13 |
| US20020028826A1 (en) | 2002-03-07 |
| HUP0302955A3 (en) | 2005-08-29 |
| ZA200210102B (en) | 2004-03-12 |
| KR20030010720A (ko) | 2003-02-05 |
| NO20026011D0 (no) | 2002-12-13 |
| PE20011364A1 (es) | 2002-02-27 |
| WO2001096311A2 (en) | 2001-12-20 |
| WO2001096311A3 (en) | 2002-07-11 |
| PL362477A1 (en) | 2004-11-02 |
| EP1294696A2 (en) | 2003-03-26 |
| CZ20023931A3 (cs) | 2003-03-12 |
| MXPA02012415A (es) | 2003-06-06 |
| AU2001266860A1 (en) | 2001-12-24 |
| IL152718A0 (en) | 2003-06-24 |
| NO20026011L (no) | 2003-02-12 |
| AR028732A1 (es) | 2003-05-21 |
| UY26776A1 (es) | 2002-01-31 |
| CA2412979A1 (en) | 2001-12-20 |
| JP2004503541A (ja) | 2004-02-05 |
| HUP0302955A2 (hu) | 2003-12-29 |
| ECSP024386A (es) | 2003-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0111571A (pt) | Inibidores de reductase de hmg-coa e seu uso como medicamentos para o tratamento de doenças relacionadas ao colesterol | |
| UA32636C2 (uk) | Засіб для зниження вмісту холестерину в сироватці крові людини | |
| GEP20022803B (en) | Steroid Sulphatase Inhibitors | |
| US20030153541A1 (en) | Novel anticholesterol compositions and method for using same | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BR0113200A (pt) | Combinação terapêutica | |
| AU7031500A (en) | Therapeutic quinazoline compounds | |
| NO872259L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive trans-6(2-(3-eller 4-karboksamido-substituert-pyrrol-1-yl)alkyl)-4-hydroksypyran-2-on-derivater. | |
| ECSP024384A (es) | INHIBIDORES DE HMG - CoA REDUCTASA Y METODO | |
| PT1256339E (pt) | Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina | |
| DE60001974D1 (de) | Derivate von flavonen, xanthonen und kumarinen | |
| ES2088959T3 (es) | 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento. | |
| BR0012610A (pt) | Novo derivado de difenilpiperidina | |
| BR9711986A (pt) | Compostos farmac-uticos | |
| DE69819514D1 (de) | Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| FR2701260B1 (fr) | Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments. | |
| KR940701251A (ko) | 콜레스테롤-강하 토코페롤 동족체 | |
| ATE233745T1 (de) | Arzneistoffe | |
| AP9901474A0 (en) | Pharmaceutical composition for treating viral diseases. | |
| EA200401295A1 (ru) | Статиновая терапия для усиления поддержания когнитивной функции | |
| WO2002006299A3 (en) | Therapeutic uses for aminosterol compounds | |
| RU95102147A (ru) | Производные 1-[2-(1н-инден-3-ил)этил]-4-(нафт-1-ил)пиперазина, способ их получения и содержащие их медикамент и фармацевтический состав | |
| DE69717279D1 (de) | Mittel gegen malaria und babesia und diese enthaltende pfarmazeutische zubereitungen | |
| RU2001124666A (ru) | Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s) -3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |